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Background: Treatment of cystic fibrosis-associated lung infections is hampered by the presence of multi-drug
resistant pathogens, many of which are also strong biofilm producers. Antimicrobial peptides, essential components
of innate immunity in humans and animals, exhibit relevant in vitro antimicrobial activity although they tend not to
select for resistant strains.
Results: Three α-helical antimicrobial peptides, BMAP-27 and BMAP-28 of bovine origin, and the artificial P19(9/B)
peptide were tested, comparatively to Tobramycin, for their in vitro antibacterial and anti-biofilm activity against 15
Staphylococcus aureus, 25 Pseudomonas aeruginosa, and 27 Stenotrophomonas maltophilia strains from cystic fibrosis
patients. All assays were carried out in physical-chemical experimental conditions simulating a cystic fibrosis lung.
All peptides showed a potent and rapid bactericidal activity against most P. aeruginosa, S. maltophilia and S. aureus
strains tested, at levels generally higher than those exhibited by Tobramycin and significantly reduced biofilm
formation of all the bacterial species tested, although less effectively than Tobramycin did. On the contrary, the
viability-reducing activity of antimicrobial peptides against preformed P. aeruginosa biofilms was comparable to
and, in some cases, higher than that showed by Tobramycin.
Conclusions: The activity shown by α-helical peptides against planktonic and biofilm cells makes them promising
“lead compounds” for future development of novel drugs for therapeutic treatment of cystic fibrosis lung disease.
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Physicians treating patients with cystic fibrosis (CF) are
increasingly faced with infections caused by multidrug-
resistant strains. Pseudomonas aeruginosa and Staphylo-
coccus aureus are the most common bacterial pathogens
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reproduction in any medium, provided the orpersistent infections associated with a more rapid de-
cline in lung function and survival [1,2]. In recent years,
however, there has been an increasing number of reports
on potentially emerging and challenging pathogens,
probably due to improved laboratory detection strategies
and to selective pressure exerted on bacterial popula-
tions by the antipseudomonal antibiotic therapy [2]. In
this respect, both the overall prevalence and incidence of
intrinsically antibiotic-resistant Stenotrophomonas mal-
tophilia isolations from CF respiratory tract secretions
have been recently reported [3-5].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Pompilio et al. BMC Microbiology 2012, 12:145 Page 2 of 10
http://www.biomedcentral.com/1471-2180/12/145Efforts to treat CF infections are also hampered by the
high microbial adaptation to the CF pulmonary environ-
ment, resulting in an increased ability to form biofilms
intrinsically resistant to therapeutically important anti-
biotics such as aminoglycosides, fluoroquinolones, and
tetracycline [6-10].
Novel antimicrobial agents that could replace or com-
plement current therapies are consequently needed to
fight chronic infections in CF patients.
Antimicrobial peptides (AMPs) are naturally occurring
molecules of the innate immune system that play an im-
portant role in the host defence of animals and plants
[11-13]. Over the last years, natural AMPs have attracted
considerable interest for the development of novel anti-
biotics for several reasons [14,15]: i) the broad activity
spectrum, comprised multiply antibiotic-resistant bac-
teria; ii) the relative selectivity towards their targets (mi-
crobial membranes); iii) the rapid mechanism of action;
and, above all, iv) the low frequency in selecting resistant
strains. Although the antimicrobial activity of AMPs has
been extensively reported in literature [13-17], only few
studies have been reported with respect to CF pathogens
[18-21].
Hence, in an attempt to evaluate the therapeutic
potential of AMPs in the management of CF lung
infections, for the first time in the present study three
cationic α-helical AMPs - two cathelicidins of bovine
origin (BMAP-27, BMAP-28) and the artificial peptide
P19(9/B) - were tested for their in vitro antibacterial
effectiveness, as well as their in vitro anti-biofilm activity,
against selected S. aureus, P. aeruginosa, and S. maltophilia
strains collected from CF patients. The efficacy of the
AMPs was compared to that of Tobramycin, selected as
the antibiotic of choice used for chronic suppressive ther-
apy in CF patients.
Since the conditions present in the CF patients’ airway
surface liquid could counteract the potency of antibiotics
such as Tobramycin [22,23], in the present study all
in vitro antimicrobial assays were carried out under ex-
perimental conditions simulating the physical-chemical
properties observed in CF lung environment [24-26].
Results
Phenotypic features and clonal relatedness of CF strains
A total of 9 out of 25 P. aeruginosa strains tested
showed mucoid phenotype on MHA, while 3 exhibited
SCV phenotype. Among 15 S. aureus isolates tested, 7
were methicillin-resistant.
PFGE analysis showed 8, 21, and 12 different pulso-
types among S. aureus, S. maltophilia, and P. aeruginosa
isolates, respectively. Among S. aureus isolates, only the
PFGE type 1 was shared by multiple strains, which com-
prised 8 isolates and 7 PFGE subtypes. Among S. malto-
philia isolates, 2 multiple-strains PFGE types wereobserved: PFGE type 23 (5 isolates, 2 PFGE subtypes),
and PFGE type 73 (2 isolates with identical PFGE pro-
file). Among P. aeruginosa isolates, 5 multiple-strains
PFGE types were observed: PFGE type 5 (6 isolates, 2
PFGE subtypes), PFGE type 1 (4 isolates with indistin-
guishable PFGE profile), PFGE types 9 and 11 (3 isolates
each, with identical PFGE pattern), and PFGE type 8 (2
isolates, one PFGE subtype) (data not shown).
In vitro activity of AMPs and Tobramycin against
planktonic cells: MIC, MBC
In order to determine the efficacy of AMPs, the anti-
microbial activity was measured against 67 CF clinical
isolates, and results are summarized in Table 1. Overall,
BMAP-28 showed the widest activity spectrum among
AMPs tested, as suggested by MIC90 and MBC90 values
(16 μg/ml, for both), although all of them exhibited a
species-specific activity. In fact, although AMPs showed
comparable activity against P. aeruginosa, BMAP-28
was found to be more active than P19(9/B) against S.
maltophilia, and resulted the best active AMP against
S. aureus (MIC90: 32 μg/ml; MBC90: 32 μg/ml). Com-
pared to AMPs, Tobramycin exhibited a lower activity
(MIC90 and MBC90: >64 μg/ml) regardless of the spe-
cies considered. Killing quotient values, calculated as
MBC/MIC ratio, were < 4 for all AMPs, as well as for
Tobramycin, clearly suggesting a bactericidal activity.
No differences in susceptibility levels to AMPs were
found with regard to phenotype (mucoid, SCV, MRSA),
pulsotype, or susceptibility to Tobramycin (data not shown).
MIC and MBC values obtained under CLSI-
recommended or “CF-like” experimental conditions (see
Materials and Methods section) are shown in Table 2.
Comparative evaluation of these values showed that
mean MICCF-like/MICCLSI and MBCCF-like/MBCCLSI
values obtained for Tobramycin (23.9 and 15.6, respect-
ively) were significantly higher than those observed for
BMAP-27 (1.5 and 1.2, respectively; p< 0.001), BMAP-
28 (0.5 and 0.5, respectively; p< 0.001), and P19(9/B)
(2.8 and 2.9, respectively; p< 0.001), regardless of spe-
cies tested, indicating a reduced antibiotic activity of
Tobramycin in CF-like conditions.
Bactericidal kinetics
Time-killing results have been summarized in Figure 1.
BMAP-27, BMAP-28, and P19(9/B) exerted a rapid bac-
tericidal activity against P. aeruginosa, reducing the num-
ber of viable bacterial cells of at least 3 logs within 60 min
of exposure. However, the bactericidal effect of BMAP-
28 against P. aeruginosa was incomplete for two (Pa6
and Pa22) of the three strains tested, allowing bacterial
regrowth after 24-h incubation, although at levels lower
than those observed for untreated control. In parallel
experiments, Tobramycin showed only a bacteriostatic
Table 1 In vitro activity of BMAP-27, BMAP-28, P19(9/B),
and Tobramycin against P. aeruginosa, S. maltophilia and
S. aureus CF strains
Bacterial strains (n) Test agent:
BMAP-27 BMAP-28 P19(9/B) TOBRAMYCIN
P. aeruginosa (25)
MIC50
a 8 16 8 16
MIC90
b 16 32 32 >64
MICrange 4-16 4–32 4–32 2-> 64
MBC50
c 8 16 16 32
MBC90
d 16 32 64 >64
MBCrange 4–16 4–64 4-> 64 2-> 64
MBC/MIC 1.3 1.2 1.9e 1.5f
S. maltophilia (27)
MIC50
a 4 4 4 >64
MIC90
b 8 4 16 >64
MICrange 4-8 2–8 4–32 4-> 64
MBC50
c 8 4 8 >64
MBC90
d 16 8 32 >64
MBCrange 4–32 2–16 4–64 8-> 64
MBC/MIC 1.9 1.3 1.7 1.3g
S. aureus (15)
MIC50
a 64 8 64 >64
MIC90
b >64 32 >64 >64
MICrange 32-> 64 4–32 32-> 64 4-> 64
MBC50
c >64 8 >64 >64
MBC90
d >64 32 >64 >64
MBCrange 64-> 64 4–32 32-> 64 4-> 64
MBC/MIC 1.2h 1.2 1.2i 1.0l
Total (67)
MIC50
a 8 4 8 >64
MIC90
b >64 16 64 >64
MICrange 4->64 2–32 4-> 64 2-> 64
MBC50
c 8 8 16 >64
MBC90
d >64 16 >64 >64
MBCrange 4-> 64 2–64 4-> 64 2-> 64
MBC/MIC 1.5m 1.2 1.7n 1.4o
a, bMIC50 and MIC90: MIC (μg/ml) inhibiting 50 and 90% of the strains tested,
respectively.
c, d MBC50 and MBC90: MBC (μg/ml) eradicating 50 and 90% of the strains
tested, respectively.
Only isolates exhibiting in range MIC values were considered for killing
quotient calculation (MBC/MIC): en = 24; fn = 12; gn = 3; hn = 6; in = 2; mn = 58;
nn = 57;on = 17.
Table 2 Antimicrobial activity of BMAP-27, BMAP-28, P19
(9/B) and Tobramycin evaluated under different
experimental conditions: “CF-like” (5% CO2, pH 6.8,
SCFM) and “standard CLSI-recommended” (aerobiosis,
pH 7.2, CAMHB)
Susceptibility (MICCF-like/MICCLSI) to:
Bacterial strains BMAP-27 BMAP-28 P19(9/B) TOBRAMYCIN
P. aeruginosa
Pa1 8/4 8/8 4/16 4/0.25
Pa5 8/4 16/16 8/8 16/2
Pa6 8/8 16/16 16/8 8/8
Pa9 8/4 16/16 16/8 64/1
S. maltophilia
Sm109 4/8 4/16 4/8 128/64
Sm126 8/16 8/32 4/32 256/64
Sm143 8/8 4/8 4/4 8/2
S. aureus
Sa1 128/64 8/16 128/16 256/64
Sa3 64/64 4/32 64/16 256/16
Sa4 64/64 4/16 32/8 32/2
Sa7 64/16 4/16 64/8 256/2
Mean MICCF-like/MICCLSI 1.5 0.5 2.8 23.9
P. aeruginosa
Pa1 8/8 8/16 16/32 4/1
Pa5 16/8 16/32 16/16 16/4
Pa6 16/8 16/16 16/32 8/8
Pa9 8/8 16/32 64/16 128/2
S. maltophilia
Sm109 8/16 8/16 8/8 256/128
Sm126 8/32 16/32 8/32 256/64
Sm143 16/8 8/8 4/4 8/8
S. aureus
Sa1 128/64 8/16 128/16 256/64
Sa3 64/64 4/32 64/16 256/32
Sa4 64/64 8/32 32/8 32/2
Sa7 64/NDa 8/16 64/8 256/4
Mean MBCCF-like/MBCCLSI 1.2 0.5 2.9 15.6
a ND, not determined.
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reduction in viable count after 24 h.
BMAP-27, BMAP-28 and P19(9/B) exerted bactericidal
activity also against S. maltophilia, although with streaking
strain-specific differences. Particularly, BMAP-28 exhibitedonly bacteriostatic effect against Sm192 strain, while P19(9/
B) showed a rapid bactericidal effect against Sm138 strain,
causing more than a 4-log reduction in viable count after
10 min-exposure. Tobramycin exhibited a late (after 24-h
exposure) bactericidal effect only against Sm138 strain.
AMPs activity against S. aureus was significantly strain-
specific, ranging from the rapid bactericidal activity of
BMAP-28 against Sa10 strain, to the bacteriostatic effect
of P19(9/B) and BMAP-28 against Sa4 strain. Tobramycin
Figure 1 Time-killing kinetic of AMPs against CF strains. BMAP-27 (■), BMAP-28 (▲), P19(9/B) (×), and Tobramycin (●) were tested at MIC
value against representative P. aeruginosa (Pa6, Pa15, and Pa22), S. maltophilia (Sm138, Sm143, and Sm192), and S. aureus (Sa4, Sa10, and Sa13) CF
strains. Controls (♦) were not exposed to drugs. Values are the mean of two independent experiments performed in triplicate. The dotted line
indicates a 3-log reduction in viability.
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tested, although allowing bacterial regrowth of Sa4 strain
after 2-h exposure.
In vitro activity of Tobramycin-AMP combinations against
planktonic cells
Results from checkerboard assays are summarized in
Table 3. FICI values showed that all AMP+Tobramycin
combinations tested showed an indifferent effect against
P. aeruginosa and S. maltophilia strains. Conversely,
BMAP-27+Tobramycin (tested at 16 + 8, 16 + 4, and
16 + 2 μg/ml, respectively) combination exhibited syner-
gic effect against Sa4 strain (the only one tested, 100%
synergy), while P19(9/B) +Tobramycin (tested at 4 + 2,Table 3 In vitro effect of AMP + Tobramycin (TOB) combinati
strains
Drug combinations P. aeruginosa S. maltoph
Synergy Indifference Antagonism Synergy
FICIa ≤ 0.5 0.5< FICI≤ 4 FICI > 4 FICI ≤ 0.5
BMAP-27+ TOB 0 (0%) 12 (100%) 0 (0%) 0 (0%)
BMAP-28+ TOB 0 (0%) 12 (100%) 0 (0%) 0 (0%)
P19(9/B) + TOB 0 (0%) 12 (100%) 0 (0%) 0 (0%)
a Fractional Inhibitory Concentration Index (FICI).
Only isolates exhibiting in-range MIC values were considered for checkerboard titra
c n = 1; d n = 3).4 + 1, and 8 + 1 μg/ml, respectively) combination exhib-
ited synergic effect against S. aureus Sa10 strain (1 out
of 3 strains tested, 33.3% synergy).
In vitro activity of AMPs and Tobramycin against biofilm
All CF strains were screened for biofilm forming ability
on polystyrene. A significantly higher proportion of bio-
film producer strains was found in P. aeruginosa and
S. aureus, compared to S. maltophilia (96 and 80% vs
55%, respectively; p< 0.01) (data not shown). However,
efficiency in biofilm formation was significantly higher
in P. aeruginosa than in S. aureus, as suggested by me-
dian biofilm amounts produced (0.162 vs 0.109, respect-
ively; p< 0.01) (data not shown).ons against P. aeruginosa, S. maltophilia, and S. aureus CF
ilia S. aureus
Indifference Antagonism Synergy Indifference Antagonism
0.5 < FICI≤ 4 FICI >4 FICI ≤ 0.5 0.5< FICI≤ 4 FICI > 4
8 (100%) 0 (0%) 1 (100%)b 0 (0%)b 0 (0%)b
8 (100%) 0 (0%) 0 (0%)c 1 (100%)c 0 (0%)c
8 (100%) 0 (0%) 1 (33.3%)d 2 (66.7%)d 0 (0%)d
tion method: P. aeruginosa (n = 12), S. maltophilia (n = 8), and S. aureus (b n = 1;
Figure 2 Effect of AMPs at sub-inhibitory concentrations
against biofilm formation by CF strains. BMAP-27 (white bars),
BMAP-28 (light gray bars), P19(9/B) (dark gray bars), and Tobramycin
(black bars) were tested at 1/2x, 1/4x, and 1/8xMIC against biofilm
formation by P. aeruginosa (n = 24, 24, 25, and 17, for BMAP-27,
BMAP-28, P19(9/B) and Tobramycin, respectively), S. maltophilia
(n = 14, 14, 27, and 5, for BMAP-27, BMAP-28, P19(9/B) and
Tobramycin, respectively), and S. aureus (n = 11, 11, 8, and 3, for
BMAP-27, BMAP-28, P19(9/B) and Tobramycin, respectively) CF
strains. Prevention of biofilm formation was plotted as percentage of
strains whose ability in forming biofilm was significantly decreased
(of at least 25%) compared to controls (not exposed), as analyzed by
a crystal violet staining assay.* p< 0.05; ** p< 0.0001, Fisher’s
exact test.
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to prevent biofilm formation, we tested the effect of
AMPs and Tobramycin at sub-inhibitory concentrations
(1/2x, 1/4x, and 1/8xMIC) against biofilm formation
(Figure 2). Tobramycin at 1/2x and 1/4xMIC caused a
significantly higher reduction in biofilm-forming ability
of S. maltophilia and S. aureus, in comparison with the
three AMPs. This effect was more relevant with
S. aureus, being observed also at 1/8xMIC. Tobramycin
showed to be more effective than BMAP-27 against
P. aeruginosa at concentrations equal to 1/4x and
1/8xMIC. The activity of Tobramycin in reducing bio-
film formation was not related to drug susceptibility
(data not shown). Among AMPs, BMAP-28 and P19(9/B)
at 1/2xMIC were significantly more active compared to
BMAP-27, and BMAP-28 at 1/4xMIC was significantly
more active than other AMPs against S. aureus.
We further evaluated AMPs as potential therapeutics
for CF by testing their efficacy against preformed bio-
films. To this, BMAP-27, BMAP-28, P19(9/B), and
Tobramycin at 1xMIC and at bactericidal concentrations
(5x, and 10xMIC) were assayed against preformed (24 h)
biofilms by six representative P. aeruginosa strains
selected for high biofilm formation ability (Figure 3).
The activity of AMPs and Tobramycin against pre-
formed biofilms resulted to be similar in 5 out of 6
strains tested, causing a highly significant reduction of
biofilm viability compared to the controls (biofilm not
exposed; p< 0.0001), regardless of the concentrations
tested (Figure 3). AMPs showed to be active at all
concentrations, also against biofilms formed by P.
aeruginosa Pa32, against which Tobramycin was ef-
fective only at the highest concentration used
(10xMIC). The activity of Tobramycin against pre-
formed biofilms was not related to drug susceptibility
(data not shown).
Discussion
This study was aimed at verifying the potential of some
α-helical AMPs as lead compounds for the development
of novel antimicrobials to treat lung disease in CF
patients. To this, we tested the in vitro susceptibility of
P. aeruginosa, S. maltophilia and S. aureus CF isolates
to the naturally occurring AMPs BMAP-27 and BMAP-
28, as well as the rationally designed P19(B/9), and we
compared their effectiveness with that of Tobramycin,
the antibiotic of choice for the inhalation therapy of
chronic airway infections in CF patients.
BMAP-27 and BMAP-28 are two cathelicidin-derived
peptides of bovine origin that have a role in innate defence
[27,28]. The hallmark of cathelicidins is the presence of a
conserved N-terminal proregion associated with C-terminal
antimicrobial sequences showing a remarkable diversity
and considerable inter-species differences [13]. BMAP-27and BMAP-28 are cationic (charge: +11 and +8, respect-
ively) and both adopt an α-helical structure on interaction
with the negatively charged bacterial surface [28]. Recent
results have suggested that AMPs with these characteristics
Figure 3 Activity of AMPs at bactericidal concentrations against preformed P. aeruginosa biofilms. BMAP-27, BMAP-28, P19(9/B), and
Tobramycin were tested at 1x (white bars), 5x (gray bars), and 10xMIC (black bars) against preformed biofilm by 6 P. aeruginosa CF strains. Results
are expressed as percentage of biofilm’ viability compared to control (not exposed, 100% viability). ** p< 0.0001, Fisher’s exact test.
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ous polysaccharides that are known to inhibit the activity of
other types of AMPs [19,29]. For this reason, we added to
our study also a third peptide from this class which has
been rationally designed, making use also of non-
proteinogenic aminoacids, to optimize its propensity to as-
sume α-helical conformation [30].
Effort to treat CF are also hampered by the conditions
present in patients’ airway surface liquid where the accu-
mulation of large volumes of viscous sputum (mucus)
providing bacteria with a nutritionally rich growth
environment composed of host- and bacterial-derived
factors which deeply change their phenotype and pos-
sibly their susceptibility against AMPs [31]. Therefore, to
accurately judge the feasibility of these peptides as
potential anti-infectives in the context of CF, in this study
we investigated the activity of AMPs under some CF-like
experimental conditions, including acidic pH, reduced O2
tension, and a chemically defined medium mimicking the
nutritional composition of CF sputum [24-26].
These conditions allow pathogens to assume a
physiology similar to that shown in vivo in the CF lung
[24] and constitute a more realistic model to assay their
sensitivity to AMPs.
Evaluation of MIC and MBC values, as well as time-
killing assays against planktonic forms of different CF
isolates of P. aeruginosa, S. maltophilia, and S. aureus,
have shown that all three AMPs are highly active
in vitro against most tested strains, although BMAP-28
showed the widest spectrum of activity. It is noteworthy
that all the three peptides exhibited an activity higher
than Tobramycin. This observation is even more evident
when considering the molar concentration (μM) of eachcompound rather than that by weight (μg/ml), given that
the peptides tested are at least six folds heavier than
Tobramycin.
The poor activity showed by Tobramycin is probably
due to the experimental conditions used in this study, as
suggested by comparative evaluation of MIC values
observed in both “CF-like” and CLSI-recommended con-
ditions. On the contrary, the activity of AMPs tested
resulted to be slightly enhanced (BMAP-28), unaffected
(BMAP-27), or slightly reduced [P19(9/B)] in “CF-like”
conditions, compared to CLSI-recommended ones, so
they can be considered to be quite robust and medium
insensitive.
MBC/MIC ratio clearly indicated that all AMPs exert
a bactericidal effect against the CF isolates, in agreement
with the known capability of BMAP-27, BMAP-28 and
P19(B/9) to kill target cells by rapid permeabilization of
their membranes [28]. Results of killing kinetic assays
confirmed this mode of action, although bactericidal ac-
tivity against S. aureus and S. maltophilia was strain-
dependent. Again, the potency of AMPs was overall
comparable or higher than that showed by Tobramycin.
Due to the different mechanism of action showed by
AMPs and Tobramycin, we investigated the potential syn-
ergy between them. Interestingly, Tobramycin exhibited
synergy with both BMAP-27 and P19(9/B) against plank-
tonic S. aureus Sa4 and Sa10 strains, both resistant to
Tobramycin, thus suggesting that at least in these cases
both AMPs may overcome resistance to Tobramycin by
facilitating the internalization of the aminoglycoside into
the bacterial cells. Further studies on a more representa-
tive number of S. aureus strains will be mandatory to
understand the mechanism of this synergy and the
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itional antibiotic treatments.
Within the CF lung, pathogens cells grow as biofilms,
which are inherently recalcitrant to antimicrobial treat-
ment and host response [32]. Even worse, it has recently
been reported that some antibiotics may even stimulate
biofilm formation at subinhibitory concentrations [7].
Biofilm resistance is mainly due to the slow growth rate
and low metabolic activity of bacteria in such commu-
nity. For these reasons, AMPs whose mechanism of ac-
tion makes them active also on non-growing bacteria,
should be able to efficiently inhibit or prevent biofilm
formation.
Our results in fact indicate that the three α-helical
peptides were all able to reduce biofilm formation, al-
though generally at a less extent than Tobramycin. In
particular, all peptides reduced the capacity of P. aerugi-
nosa, S. maltophilia and S. aureus to form biofilms when
used at sub-inhibitory concentrations, with the strongest
effects at about 1/2xMIC values, while Tobramycin was
efficacious also at lower concentrations (1/4x, and 1/8x
MIC). This effect was particular evident with the isolates
of S. aureus. Interestingly, no planktonic growth inhib-
ition was observed at concentrations able to reduce bio-
film formation, and also AMPs with poor killing
capacity against some planktonic cells showed anti-
biofilm effects. These observations suggest that BMAP-
27, BMAP-28 and P19(9/B) may interfere with biofilm
formation by different mechanisms other than direct
antimicrobial activity similarly to what observed with the
human cathelicidin LL-37 [33], and recently reviewed by
Batoni et al. [34].
Most CF patients are infected by P. aeruginosa whose
persistence is due to the formation of antibiotic resistant
biofilms in the lung [35]. Our results showed that
BMAP-27, BMAP-28, and P19(9/B) were also as effective
as Tobramycin in reducing cell viability of preformed bio-
films formed by selected strains of P. aeruginosa. At MIC
concentrations, and even more at 5xMIC values, the two
cathelicidins caused highly significant reduction of bio-
film viability of all six strains of P. aeruginosa whereas
Tobramycin showed comparable results only for five iso-
lates. It has previously been reported that extracellular
DNA is an important biofilm component [36], and that
in P. aeruginosa it is involved in cell-cell attachment and
biofilm development [37]. Due to the high affinity of cat-
ionic AMPs for DNA [38], it may be presumed that this
binding might facilitate the detachment or disruption of
otherwise-stable biofilm structures.
Conclusions
The overall results of this study shed new insights on
the antibacterial properties of α-helical peptides, allow-
ing the selection of those with the best properties tocope with lung pathogens associated to CF. BMAP-27,
BMAP-28 and also the rationally designed P19(9/B) may
thus be considered useful not only as lead compounds
for the development of novel antibiotics but also for
compounds that may counteract bacterial biofilm forma-
tion and eradicate preformed biofilms, reflecting the
modern understanding of the role of biofilm formation
in chronic CF infections. However, before applying these
molecules in the future for early prophylactic and thera-
peutic treatment of CF lung disease, further in vitro
studies (against other CF pathogens, such as Burkhol-
deria cepacia, and fungi), as well as in vivo studies are
needed to evaluate their therapeutic potential.
Methods
Bacterial strains
Overall, 67 antibiotic-resistant bacterial strains were
tested in the present study: 15 S. aureus, 25 P. aerugi-
nosa, and 27 S. maltophilia. Strains were collected from
respiratory specimens obtained from patients admitted
to the CF Operative Unit, “Bambino Gesù” Children’s
Hospital and Research Institute of Rome. Identification
to species level was carried out by both manual (API
System; bioMérieux, Marcy-L'Etoile, France) and auto-
mated (BD Phoenix; Becton, Dickinson and Company,
Buccinasco, Milan, Italy) biochemical test-based systems.
Each isolate was collected from a single patient and re-
sistant to at least three of the following groups of anti-
biotics: β-lactams with or without β-lactamase inhibitor,
aminoglycosides, fluoroquinolones, folate-pathway inhi-
bitors (trimethoprim-sulphamethoxazole), tetracyclines,
and macrolides. Strains were stored at −80°C in a Micro-
bank system (Biolife Italiana S.r.l., Milan, Italy) and sub-
cultured in Trypticase Soya broth (Oxoid S.p.A., Milan,
Italy), then twice on Mueller-Hinton agar (MHA; Oxoid
S.p.A) prior to the use in this study.
Phenotypic and genotypic characterization of CF strains
All strains grown on MHA were checked for mucoid
phenotype and the emergence of small-colony variants
(SCVs). Further, they were screened for their susceptibility
to antibiotics by agar-based disk diffusion assay, according
to the CLSI criteria [39], and by the Etest following the
manufacturer’s instructions assays (Biolife Italiana S.r.l.;
Milan, Italy).
All CF strains tested in this study were genotyped by
Pulsed-Field Gel Electrophoresis (PFGE) analysis in
order to gain clue on genetic relatedness of strains. DNA
was prepared in agarose plugs for chromosomal macro-
restriction analysis as previously described [40,41]. For
S. aureus isolates, agarose plugs were digested with
enzyme SmaI (40U). DNA from P. aeruginosa and
S. maltophilia isolates was digested using XbaI (30U).
PFGE profiles were visually interpreted following the
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particular, isolates with indistinguishable PFGE patterns
were assigned to the same PFGE subtype; for S. aureus,
isolates differing by 1 to 4 bands were assigned to dif-
ferent PFGE subtypes within the same PFGE type; for
S. maltophilia and P. aeruginosa, isolates were assigned
to the same PFGE type with different PFGE subtypes
when they differed by 1 to 3 bands.
Peptide Synthesis, purification and characterization
P19(9/B) (GZZOOZBOOBOOBZOOZGY; where Z =
Norleucine; O = Ornithine; B = 2-Aminoisobutyric acid)
was a kind gift of Prof. A. Tossi and was prepared as
described previously [30]. BMAP-27 (GRFKRFRKKFK-
KLFKKLSPVIPLLHL-am) and BMAP-28 (GGLRSLGRKI-
LRAWKKYGPIIVPIIRI-am) were synthesised as C-terminal
amides by solid-phase peptide Fmoc strategy on a
Microwave-enhanced CEM Liberty Synthesizer on a Pal-
PEG Rink Amide resin LL (substitution 0.18-0.22 mmol/
g). The peptides were purified by RP-HPLC on a Phe-
nomenex preparative column (Jupiter™, C18, 10 μm,
90 Å, 250 × 21.20 mm) using a 20-50% CH3CN in 60-
min gradient with an 8 ml/min flow. Their quality and
purity were verified by ESI-MS (API 150 EX Applied
Biosystems). Concentrations of their stock solutions,
were confirmed by spectrophotometric determination of
tryptophan (E280 = 5500 M
-1 cm-1), by measuring the dif-
ferential absorbance at 215 nm and 225 nm [42] and by
spectrophotometric determination of peptide bonds (E214
calculated as described by Kuipers and Gruppen [43]).
“CF-like” experimental conditions
In order to simulate the physical-chemical properties
observed in CF lung environment [24-26], all in vitro
antimicrobial assays against planktonic (MIC, MBC,
time-kill kinetics, synergy testing) and sessile (biofilm
formation, preformed biofilms) cells were performed in
“CF-like” conditions: i) under reduced oxygen concen-
tration (5% CO2); ii) at acidic pH (6.8); and iii) in a
chemically defined “synthetic CF sputum medium”
(SCFM), that mimics the nutritional composition of CF
sputum [24]. SCFM was prepared by using Casamino
Acids Vitamin Assay (BD Difco) mixture containing
each amino acid at concentration not significantly differ-
ent from that originally described by Palmer and co-
workers [24], except for a reduced amount of glycine
and ornithine, which were therefore added from ad hoc
prepared stock solutions to reach their required
concentration.
Susceptibility testing
MICs and MBCs were determined by microdilution
technique, in accordance with CLSI M100-S20 protocol
[39], with some modifications. Briefly, serial two-folddilutions (64 to 0.12 μg/ml) of each AMP and Tobra-
mycin (Sigma-Aldrich S.r.l.; Milan; Italy) were prepared
in SCFM at a volume of 100 μl/well in 96-well microtiter
plates (Bibby-Sterilin Italia S.r.l.; Milan, Italy). Each well
was then inoculated with 5 μl of a standardized inocu-
lum, corresponding to a final test concentration of about
0.5-1 × 105 CFU/well. After incubation at 37°C for 24 h,
the MIC was read as the lowest concentration of the
test agent that completely inhibited visible growth. To
measure the MBC, 100 μl of broth from clear wells were
plated on MHA plates, and incubated at 37°C for 24 h.
MBC was defined as the lowest concentration of the test
agent killing of at least 99.99% of the original inoculum.
To evaluate the impact of “CF-like” experimental con-
ditions on the antimicrobial activity of AMPs and
Tobramycin, a set of PFGE-unrelated isolates represen-
tative for different levels of susceptibility to Tobramycin
(4 P. aeruginosa, 3 S. maltophilia, and 4 S. aureus) was
also tested for MIC and MBC values determined under
standard CLSI-recommended conditions (i.e., aerobic at-
mosphere, cation-adjusted Mueller-Hinton broth, and
pH 7.2).Time-killing assay
Kinetics of AMPs’ and Tobramycin’ activity was evaluated
by using the broth macrodilution method against three
representative isolates within each tested species. Briefly,
the standardized inoculum (1x105 CFU/mL) was exposed
to the test agent at 1xMIC in SCFM, and incubated at
37°C. After 10 min, 30 min and 1, 2, and 24-h of
incubation, aliquots of each sample were diluted and
plated onto MHA, then the viable counts determined
after 24-h of incubation at 37°C. Killing curves were
constructed by plotting the log CFU/mL versus time.Synergy testing
The activity of each AMP combined to Tobramycin
against CF strains was evaluated by checkerboard tech-
nique by using 96-well polystyrene microplate (Kartell S.
p.A., Noviglio, Milan, Italy). Briefly, concentrations of
multiple compounds (range: 64–0.12 μg/ml) were com-
bined in standard MIC format along with 5 × 105 CFU/
ml of tested. Inoculated microplates were incubated at
37°C for 24 h under 5% CO2. At the end of the incuba-
tion, for each combination interaction a Fractional In-
hibitory Concentration (FIC) index was calculated as
follows: FIC index = Σ (FICA + FICB), where FICA is the
MIC of drug A in the combination/MIC of drug A
alone, and FICB is the MIC of drug B in the combin-
ation/MIC of drug B alone. Synergy was defined as a
FIC index of ≤0.5, indifference as a FIC index of >0.5 to
≤ 4, and antagonism as a FIC index of > 4.
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In each well of a 96-well flat-bottom polystyrene tissue-
culture microtiter plate (Iwaki; Bibby-Sterilin Italia S.r.l.),
5 μl of a standardized inoculum (1–5 × 107 CFU/ml)
were added to 100 μl of SCFM containing test agent at
1/2x, 1/4x, and 1/8xMIC. After incubation at 37°C for
24 h, non-adherent bacteria were removed by washing
twice with 100 μl sterile PBS (pH 7.2; Sigma-Aldrich
S.r.l.). Slime and adherent cells were fixed by incubating
for 1 h at 60°C, and stained for 5 min at room
temperature with 100 μl of 1% crystal violet solution.
The wells were then rinsed with distilled water and dried
at 37°C for 30 min. Biofilms were destained by treatment
with 100 μl of 33% glacial acetic acid for 15 min, and the
OD492 was then measured. The low cut-off was repre-
sented by approximately 3 standard deviations above the
mean OD492 of control wells (containing medium alone
without bacteria). The percentage of inhibition was cal-
culated as follows: (1 – OD492 of the test/OD492 of non-
treated control) x 100.
In vitro activity against preformed P. aeruginosa biofilms
In vitro activity of AMPs and Tobramycin was evaluated
against biofilms formed by 6 P. aeruginosa strains,
selected because strong biofilm-producers. Biofilms were
allowed to form in each well of a 96-well flat-bottom
polystyrene tissue-treated microtiter plate (Iwaki), as
described above. Biofilms samples were then exposed to
100 μl of drug-containing SCFM (prepared at 1x, 5x,
and 10x MIC). After incubation at 37°C for 24 h, non-
adherent bacteria were removed by washing twice with
100 μl sterile PBS (pH 7.2), and biofilm samples were
scraped with a pipette tip following 5-min exposure to
100 μl trypsin-EDTA 0.25% (Sigma-Aldrich S.r.l.). Cell
suspension was then vortexed for 1 min to break up bac-
terial clumps. Bacterial counts were assessed by plating
serial 10-fold dilutions of the biofilm cell suspension on
MHA plates.
Statistical analysis
All experiments were performed at least in triplicate
and repeated on two different occasions. Differences
between frequencies were assessed by Fisher's exact
test. Statistical analysis of results was conducted with
GraphPad Prism version 4.00 (GraphPad software Inc.;
San Diego, CA, USA), considering as statistically sig-
nificant a p value of < 0.05.
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